SENTI BIOSCIENCES INC. - COMMON STOCK

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

13 May 2024 07:15:53 By Nasdaq GlobeNewswire

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

09 May 2024 15:05:33 By Nasdaq GlobeNewswire

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

30 Apr 2024 07:05:36 By Nasdaq GlobeNewswire

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

21 Mar 2024 15:05:49 By Nasdaq GlobeNewswire

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

05 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

22 Dec 2023 05:30:00 By Nasdaq GlobeNewswire

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

13 Nov 2023 15:15:00 By Nasdaq GlobeNewswire

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

06 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

31 Oct 2023 08:06:00 By Nasdaq GlobeNewswire

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

27 Sep 2023 08:05:00 By Nasdaq GlobeNewswire

Senti Bio to Participate in Upcoming Conferences

26 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Senti Bio to Participate in Upcoming Investor Conferences

05 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

11 Aug 2023 07:35:00 By Nasdaq GlobeNewswire

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

10 Aug 2023 07:35:00 By Nasdaq GlobeNewswire

Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

20 May 2023 07:05:00 By Nasdaq GlobeNewswire

Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

09 May 2023 15:05:01 By Nasdaq GlobeNewswire

Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

02 May 2023 15:45:00 By Nasdaq GlobeNewswire

Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

17 Apr 2023 07:45:00 By Nasdaq GlobeNewswire

Senti Bio to Participate in Upcoming Investor Conferences

14 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

22 Mar 2023 16:09:13 By Nasdaq GlobeNewswire